CI-959
CI-959 is an orally active cell activation inhibitor. CI-959 selectively suppresses inflammatory cell activation post-receptor signaling via inhibiting calcium influx and weak calmodulin antagonism, without targeting PLC, PKC or NADPH oxidase. CI-959 blocks lung allergic mediator release, anti-IgE bronchial contraction, neutrophil function, T-cell proliferation and DC marker expression while sparing monocytes. CI-959 provides gastric cytoprotection by inhibiting leukocyte adhesion and suppresses tumor motility through F-actin reduction. CI-959 can be used for research on allergies, inflammation, autoimmune diseases, gastric injury, and tumor metastasis .
For research use only. We do not sell to patients.
- CAS No.: 104795-68-8
- Formula: C14H15N5NaO3S
- Molecular Weight:356.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Calcium Channel Isoforms
More
Biological Activity
Description
|
Calcium Channel |
F-actin |
In Vitro
CI-959 (0.1-100 μM) inhibits spontaneous neutrophil migration and fMLP-induced chemotaxis in human peripheral blood neutrophils, with IC50 values of 3.6 and 3.1 μM, respectively[3].
CI-959 (100 μM) shows no significant inhibition of fMLP receptor binding in human peripheral blood neutrophils, but only mildly inhibits phagocytosis of opsonized yeast[3].
CI-959 (0.1-100 μM) selectively inhibits respiratory burst induced by stimuli that promote calcium mobilization or calcium influx in human peripheral blood neutrophils, but does not act on NADPH oxidase itself and does not have oxygen free radical scavenging activity[3].
CI-959 (0.1-100 μM) selectively suppresses primary granule degranulation, with negligible activity against secondary granule secretion and PKC-dependent degranulation; it has no direct enzyme inhibition or cytotoxicity in human peripheral blood neutrophils[3].
CI-959 acts upstream of arachidonic acid metabolism via calcium signaling, without direct inhibition of 5-LO or COX enzymes in human peripheral blood neutrophils[3].
CI-959 (100 μM) targets downstream of PLC and IP3 receptor, blunts neutrophil calcium signaling by inhibiting extracellular Ca2+PKC in human peripheral blood neutrophils[3].
CI-959 (5-10 μM) directly blocks inflammatory mediator-induced leukocyte-endothelial adhesion without disturbing microcirculatory hemodynamics[4].
CI-959 (0.0075-75 μM; 10 min) potently inhibits immunologically induced mediator release from human and guinea pig lung in vitro, with marked suppression of histamine and leukotriene release[5].
CI-959 (1-10 μM; 10 min) almost completely inhibits anti-IgE-induced human bronchial smooth muscle contraction[5].
CI-959 (0.3-100 μM; 24 h) concentration-dependently inhibits Con A (Concanavalin A (Biotinylated)) (HY-NP0174)-stimulated IL-2 release in rat spleen cells and human lymphocytess[6].
CI-959 (0.03-300 μM) potently suppresses ConA-triggered proliferation (IC50=4.7 μM for rat splenocytes, 5.4 μM for human lymphocytes) and MLR responses (IC50=3.5 μM), and this ConA inhibitory effect cannot be rescued by exogenous IL-2s[6].
CI-959 (0.01-100 μM) rapidly and in a concentration-dependent manner inhibits the spontaneous polarity of Walker carcinosarcoma cells, and this effect is reversible[7].
CI-959 (10 μM; 30 min) almost completely inhibits the spontaneous motility of Walker carcinosarcoma cells[7].
CI-959 (0.001-100 μM) concentration-dependently reduces F-actin content in Walker carcinosarcoma cells, closely correlating with inhibition of cell polarity[7].
CI-959 (0.01-30 μM; 30 min) inhibition of Walker cell polarity is independent of extracellular calcium[7].
CI-959 (30 μM) only induces minor shifts of intracellular calcium, and its anti-motile function persists under low-calcium conditions, ruling calcium signaling as its primary mechanism[7].
CI-959 (1-100 μM; 24-72 h) has no direct hypertrophic effect on cardiomyocytes; cardiac hypertrophy is not a direct compound effect[8].
CI-959 (0.67 nM-6.7 μM; 30 min) has minimal direct β-adrenoceptor binding activity, ruling out direct catecholaminergic effects[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | Cmax | AUC |
|---|---|---|---|---|
| Rat[8] | 10 mg/kg | i.v. | 69 μg/mL | 27.6 μg·h/mL |
| Rat[8] | 100 mg/kg | p.o. | 24.1 μg/mL | 311 μg·h/mL |
| Rat[8] | 150 mg/kg | p.o. | 36.6 μg/mL | 606 μg·h/mL |
| Rat[8] | 20 mg/kg | i.v. | 142 μg/mL | 152 μg·h/mL |
| Rat[8] | 25 mg/kg | p.o. | 6.02 μg/mL | 35.1 μg·h/mL |
| Rat[8] | 3 mg/kg | i.v. | 23.9 μg/mL | 2.43 μg·h/mL |
| Rat[8] | 30 mg/kg | i.v. | 174 μg/mL | 557 μg·h/mL |
| Rat[8] | 50 mg/kg | p.o. | 13.5 μg/mL | 109 μg·h/mL |
In Vivo
CI-959 (10-90 mg/mL; intranasal instillation; once daily; for 14 days) has local toxicity to the respiratory epithelium of the canine nasal cavity[1].
CI-959 (25-75 mg/kg; p.o.; once daily; for 14 days) exhibits no significant immunotoxicity in rats at doses that do not alter body weight or organ weights[2].
CI-959 (25-75 mg/kg; p.o.; once daily; for 14 days) does not impair the host resistance of mice to bacteria and tumors[2].
CI-959 (0.0001-100 mg/kg; p.o.; single dose) exhibits potent cytoprotective activity against NSAID (Aspirin (HY-14654), Indomethacin (HY-14397)) and ethanol-induced gastric mucosal damage in Sprague-Dawley rat, with ED50 values of 0.05 mg/kg (aspirin), 1.0 mg/kg (indomethacin), and 0.07 mg/kg (ethanol), respectively[4].
CI-959 (5 mg/kg; p.o.; single dose) prophylactic administration reduces the severity of gastric damage but does not accelerate the healing process after injury in Sprague-Dawley rat[4].
CI-959 (5 mg/kg; p.o.; once daily) has no significant effect on the healing rate of gastric injuries induced by ethanol or indomethacin in Sprague-Dawley rat[4].
CI-959 (50-200 mg/kg; p.o.; single dose) does not inhibit gastric acid secretion in a rat basal gastric acid secretion model[4].
CI-959 (0.1-10 mg/kg; p.o.; single dose) dose not inhibit gastric acid secretion in a Beagle dog model of stimulated gastric acid secretion[4].
CI-959 (2-50 mg/kg; p.o.; single dose) ’s protective effect on gastric cells does not involve the inhibition of the arachidonic acid metabolic pathway in Sprague-Dawley rat[4].
CI-959 (0.1-100 mg/kg; p.o.; single dose) does not exert cytoprotective effects via regulating intracellular sulfhydryl levels in Sprague-Dawley rat[4].
CI-959 (1-10 mg/kg; p.o.; single dose) effectively inhibits indomethacin-induced leukocyte adhesion in Sprague-Dawley rat[4].
CI-959 (25 mg/kg; i.v.; single dose) exhibits gastric cytoprotection after intravenous administration in Sprague-Dawley rat, indicating that its protective effect is independent of local gastrointestinal effects[4].
CI-959 (3-30 mg/kg; i.v.; once daily; for 14 days) induces reversible cardiac hypertrophy in male Wistar rats, with no myocardial injury or CPK/LDH isozyme changes[8].
CI-959 (30-100 mg/kg; i.v.; once daily; for 10.5 days) fails to induce cardiac hypertrophy without high plasma drug peaks in Male Wistar rats, confirming Cmax as the critical toxic determinant[8].
CI-959 (25 mg/kg; i.v.; once daily; for 10 days)-associated cardiac hypertrophy is mediated by endogenous catecholaminergic stimulation of cardiac β1-adrenoceptors in Male Wistar rats[8].
CI-959 (100 mg/kg; p.o.; once daily; for 7 days) only triggers mild transient hypotension and slight brief catecholamine elevation in Male Wistar rats, while dopamine levels stay constant[8].
CI-959 (25 mg/kg; i.v.; once daily; for 7 days) induces persistent hypotension and marked rises in plasma epinephrine and norepinephrine without compensatory tachycardia in Male Wistar rats[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (85-127 days old, weighing 253-367 g)[1]
-
Dosage:0.5 mg/mL, 2 mg/mL, 10 mg/mL, 20 mg/mL, 30 mg/mL, 60 mg/mL, 90 mg/mL
-
Administration:Intranasal instillation, once daily, for 14 days
-
Result:Did not cause nasal lesions at 0.5 mg/mL.
Only a few small degenerative foci of the olfactory epithelium in a small number of female animals at 2 mg/mL.
Dose-dependent nasal mucosal degeneration was detected at all four nasal tissue levels in rats, characterized by epithelial disorganization, intracellular edema, mucosal thinning, cellular sloughing and necrosis at concentrations ≥10 mg/mL.
Adhesions and fibrous osteophytes appeared at concentrations ≥20 mg/ml.
Bilateral lesions and serous luminal exudate appeared at 60-90 mg/mL.
Increased salivation was observed in male mice at concentrations ≥20 mg/mL.
Increased salivation was observed in female mice at concentrations ≥60 mg/mL.
Decreased body weight or reduced weight gain was observed in female mice in the 60-90 mg/mL group.
-
Animal Model:Beagle dogs (Marshall Farms),(1-3 years old, weighing 8-14 kg)[1]
-
Dosage:10 mg/mL, 20 mg/mL, 30 mg/mL, 60 mg/mL, 90 mg/mL
-
Administration:Intranasal instillation, once daily, for 14 days
-
Result:Intranasal instillation, once daily, for 14 days No nasal mucosal damage was observed at 10 mg/mL.
Respiratory epithelial degeneration occurred at concentrations ≥20 mg/ml, characterized by loss of cilia and goblet cells, mucosal thinning, and squamous or transitional metaplasia; lesion severity and extent increased with concentration.
Almost all dogs treated with the medication experienced salivation, but this was not related to the dosage.
Had no effect on body weight, food intake, or body temperature.
-
Animal Model:Male Fischer 344 rats (6-7 weeks)[2]
-
Dosage:25 mg/kg, 50 mg/kg, 75 mg/kg
-
Administration:p.o., once daily, for 14 days
-
Result:Had no significant effect on the percentage of T and B cells in the spleen or the total number of spleen cells.
Significantly reduced NK cell activity, but in no dose-dependent manner.
Had no significant effect on Con A and PWM-induced lymphocyte proliferation.
Significant reductions in AFC/106 cells and AFC/spleen at 75 mg/kg were observed on days 4 and 5.
Reduced spleen weight, but had no significant effect on the clearance half-life of 51Cr-sRBCs, liver and spleen uptake.
Significantly reduced NK cell activity (approximately 15-18% inhibition) at 50 and 75 mg/kg, but this was not dose-dependent.
-
Animal Model:Female B6C3F1 mice (6-8 weeks)[2]
-
Dosage:25 mg/kg, 50 mg/kg, 75 mg/kg
-
Administration:p.o., once daily, for 14 days
-
Result:None of the bacterial challenge doses altered the host resistance of mice to Streptococcus pneumoniae.
None of the bacterial challenge doses altered the host resistance of mice to Listeria monocytogenes.
The number of lung nodules and CPM/lung ratio were comparable to those in the control group at each tumor cell attack dose.
-
Animal Model:Female Sprague-Dawley rats weighting 180-300 g[4]
-
Dosage:0.0001-100 mg/kg
-
Administration:p.o., single dose
-
Result:Provided dose-dependent gastric mucosal protection against aspirin (ED50 = 0.05 mg/kg), indomethacin (ED50 = 1.0 mg/kg), and ethanol (ED50 = 0.07 mg/kg).
Prevented ethanol-induced mucosal and submucosal edema and hemorrhage at 10 mg/kg.
-
Animal Model:Female Sprague-Dawley rats weighting 180-300 g[4]
-
Dosage:5 mg/kg
-
Administration:p.o., single dose
-
Result:Showed lower damage levels than the solvent group at all time points, with an average cytoprotective effect of approximately 86%, but the healing rate was parallel to that of the solvent group.
-
Animal Model:Female Sprague-Dawley rats weighting 180-300 g[4]
-
Dosage:5 mg/kg
-
Administration:p.o., once daily
-
Result:Had no significant effect on the healing rate of gastric injuries induced by ethanol or indomethacin.
-
Animal Model:Shay pylorus-ligated rat weighting 140-240 g[4]
-
Dosage:50 mg/kg, 200 mg/kg
-
Administration:p.o., single dose
-
Result:Had no significant effect on basal gastric acid secretion.
-
Animal Model:Gastric fistula female beagle dogs weighting 7-11 kg[4]
-
Dosage:0.1 mg/kg, 1 mg/kg, 10 mg/kg
-
Administration:p.o., single dose
-
Result:Had no effect on Dimaprit (Dimaprit dihydrochloride) (HY-B1478)-stimulated gastric acid secretion.
-
Animal Model:Female Sprague-Dawley rats weighting 180-300 g[4]
-
Dosage:2 mg/kg, 10 mg/kg, 50 mg/kg
-
Administration:p.o., single dose
-
Result:Had no significant inhibitory effect on the production of PGE2 and LTC4 in the gastric mucosa stimulated by ethanol.
-
Animal Model:Female Sprague-Dawley rats weighting 180-300 g[4]
-
Dosage:0.1 mg/kg, 1 mg/kg, 10 mg/kg, 100 mg/kg combined with NEM (50 mg/kg)
-
Administration:p.o. combined with NEM (s.c.), single dose
-
Result:Showed no significant change in gastric cytoprotection after NEM ( N-Ethylmaleimide) (HY-D0843) co-administration.
-
Animal Model:Female Sprague-Dawley rats weighting 180-300 g[4]
-
Dosage:1 mg/kg, 5 mg/kg, 10 mg/kg
-
Administration:p.o., single dose
-
Result:Completely inhibited indomethacin-induced leukocyte adhesion at 5 and 10 mg/kg.
-
Animal Model:Female Sprague-Dawley rats weighting 180-300 g[4]
-
Dosage:25 mg/kg
-
Administration:i.v., single dose
-
Result:Exhibited gastric cytoprotection after intravenous administration.
-
Animal Model:Exhibited gastric cytoprotection after intravenous administration.
-
Dosage:3 mg/kg, 10 mg/kg, 30 mg/kg
-
Administration:i.v., once daily, for 14 days
-
Result:No cardiac morphological or biochemical changes at 3 mg/kg for 14 days.
Ventricular wall thickening and massive myocardial glycogen accumulation appeared at day 7 with 10 and 30 mg/kg.
Right ventricular hypertrophy occurred at day 14 for 30 mg/kg.
Glycogen accumulation and myocyte enlargement; no degeneration or necrosis, all these changes completely reversible after 14-day withdrawal.
Increased Heart wet weight, dry weight, and total protein.
Induced cardiac hypertrophy was not associated with CPK or LDH isozyme changes.
-
Animal Model:Male Wistar rats (weighting 150-250 g)[8]
-
Dosage:30 mg/kg
-
Administration:i.v., once daily, for 10.5 days
-
Result:Daily IV bolus increased heart weight by 35%.
Ontinuous infusion at 30/100 mg/kg/day resulted in steady-state plasma levels of only 3.1 and 10 μg/mL.
Continuous infusion had no effect on heart weight.
Was undetectable in plasma 24 hours after the last administration in the intravenous bolus group.
-
Animal Model:Male Wistar rats (weighting 150-250 g)[8]
-
Dosage:25 mg/kg
-
Administration:i.v., once daily, for 10 days
-
Result:Triggered cardiac hypertrophy and glycogen accumulation were completely abolished by central sympatholytics (Clonidine (HY-12721)), nonselective β-blockers (D,L-propranolol and L-propranolol) and β₁-selective antagonists (Atenolol (HY-17498) and Practolol (HY-119802)).
-
Animal Model:Male Sprague-Dawley rats (weighting 328-477 g)[8]
-
Dosage:100 mg/kg
-
Administration:p.o., once daily, for 7 days
-
Result:Produced only slight BP reduction of 11 mmHg.
Produced only transient catecholamine increase, returning by 4 h.
-
Animal Model:Male Sprague-Dawley rats (weighting 328-477 g)[8]
-
Dosage:25 mg/kg
-
Administration:i.v., once daily, for 7 days
-
Result:Produced sustained BP reduction of 20-26 mmHg, maximal at 1-2 h, recovery at 5-6 h.
Produced significant and prolonged increase in plasma Epi and NE, peaking at 1 h, sustained for at least 4 h.
Chemical Information
-
CAS No. 104795-68-8
-
Molecular Weight 356.36
-
Formula C14H15N5NaO3S
-
SMILES
COC1=CC=C2C(C(OC(C)C)=C(C(NC3=NN=NN3)=O)S2)=C1.[Na]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Ca2+ Staining Technique
Ca2+ staining is an experimental technique that utilizes specific fluorescent probes (such as Fluo-4 AM, Fura-2, etc.) to qualitatively or quantitatively detect dynamic changes in intracellular Ca2+ concentrations; this is achieved by monitoring the changes in fluorescent signals generated when these probes bind to free intracellular calcium ions. The underlying principle relies primarily on the presence of chelating groups within the probe's molecular structure that possess high affinity for calcium ions.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Phalloidin F-actin cytoskeleton staining
Phalloidin F-actin staining detects polymerized filamentous actin in fixed and permeabilized specimens by using fluorescent phalloidin or phalloidin-derived phallotoxins that bind actin filaments and generate a fluorescence microscopy readout corresponding to F-actin organization, including stress fibers, cortical actin, filament bundles, and tissue-specific actin networks. Phalloidin stabilizes F-actin by reducing actin subunit dissociation from filament ends, and fluorescent phallotoxins were established as tools for visualizing actin-containing structures in eukaryotic cells.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
[1]. Walsh KM, et al. Nasal toxicity of CI-959 free acid, a novel anti-inflammatory drug, in Wistar rats and Beagle dogs. Toxicol Pathol. 1998 Nov-Dec;26(6):717-23. [Content Brief]
[2]. Bleavins MR, et al. Immunotoxicologic studies with CI-959 free acid, a novel benzothiophene cell activation inhibitor. Toxicology. 1995 Apr 12;98(1-3):111-23. [Content Brief]
[3]. Wright CD, et al. Selective regulation of human neutrophil functions by the cell activation inhibitor CI-959. J Leukoc Biol. 1994 Apr;55(4):443-51. [Content Brief]
[4]. Low J, et al. Cytoprotective effects of CI-959 in the rat gastric mucosa: modulation of leukocyte adhesion. Gastroenterology. 1995 Oct;109(4):1224-33. [Content Brief]
[5]. Adolphson RL, et al. CI-959, a new, potential antiallergic drug, inhibits mediator release from lung and contractions of human airways in vitro. Int Arch Allergy Appl Immunol. 1990;93(2-3):267-71. [Content Brief]
[6]. Dong MK, et al. Inhibition of interleukin-2 production and lymphocyte responsiveness by the cell activation inhibitor, CI-959. Agents Actions. 1991 Sep;34(1-2):53-5. [Content Brief]
[7]. von Tscharner Biino N, et al. Suppression of polarity, locomotion and F-actin levels of Walker carcinosarcoma cells by the inhibitor CI-959. Life Sci. 1997;61(2):137-45. [Content Brief]
[8]. Low JE, et al. Cardiac hypertrophy in rats after intravenous administration of CI-959, a novel antiinflammatory compound: morphologic features and pharmacokinetic and pharmacodynamic mechanisms. J Cardiovasc Pharmacol. 1995 Jun;25(6):930-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)